MBX Biosciences is trading 10.1% up now at $70.88 as traders position ahead of its upcoming earnings report, expected around August 5–6, 2026.
- Investor confidence is bolstered by a prior Q1 2026 EPS beat, which continues to provide tailwinds for the stock.
- The move is further supported by a broad risk-on rally in U.S. equities and strength in the biotech sector, with the XBI gaining approximately 2%.